Xenetic Biosciences, Inc.
XBIOHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Xenetic Biosciences, Inc. (XBIO) is listed under Biotechnology. Valued at $4.0M, XBIO is a micro-cap name in its sector. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
Market Cap
$4.0M
Beta
2.20
P/E (TTM)
—
P/E (Fwd)
-2.61
EPS (TTM)
$-1.15
EPS (Fwd)
$-0.66
ROE
-47.0%
ROA
-26.8%
Cash
$6.5M
Total Debt
$0
Free CF
-$1.2M
52W Change
-54.1%
Annual Financials
Cash vs Debt
Where XBIO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, XBIO finished 36.09% below its 150-day moving average ($3.02) and 32.28% below its 200-day moving average ($2.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XBIO overbought or oversold?
At the October 20, 2026 close, XBIO's RSI(14) was 24.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Xenetic Biosciences, Inc. reports $6.5M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$1.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -47.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.7M (2022) to $3.0M (2025), reflecting a 74% increase over the period.
Xenetic Biosciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Xenetic Biosciences, Inc. and its sector.